Colorectal carcinogenesis-update and perspectives

World Journal of Gastroenterology

Volumn 20, Issue 48, 2014, Pages 18151-18164

  Raskov, Hans ^a   Pommergaard, Hans Christian ^b   Burcharth, Jakob ^b   Rosenberg, Jacob ^b  

^a Diakonissestiftelsen Specialist Center   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Colorectal carcinogenesis; Diet; Genetics; Inflammation; Microbiology; Microbiome; Risk factors

Indexed keywords

AMMONIA; APC PROTEIN; B RAF KINASE; BILE ACID; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; NITROGEN; PROTEIN P53; VASCULOTROPIN RECEPTOR; TUMOR MARKER;

ALCOHOL CONSUMPTION; ARACHIDONIC ACID METABOLISM; ARTICLE; CALORIC INTAKE; CANCER GENETICS; CANCER RISK; CANCER SCREENING; CARCINOGENESIS; CHROMOSOMAL INSTABILITY; COLONOSCOPY; COLORECTAL CANCER; DIETARY INTAKE; GENE MUTATION; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; INFLAMMATORY BOWEL DISEASE; MICROSATELLITE INSTABILITY; MOLECULAR BIOLOGY; NONHUMAN; OCCULT BLOOD; SMOKING; ADVERSE EFFECTS; ANIMAL; CELL TRANSFORMATION; COLON; COLORECTAL NEOPLASMS; DIET; DRINKING BEHAVIOR; GENETIC PREDISPOSITION; GENETICS; LIFESTYLE; METABOLISM; PATHOLOGY; PREVENTION AND CONTROL; PROTECTION; RISK ASSESSMENT; RISK FACTOR;

ALCOHOL DRINKING; ANIMALS; BIOMARKERS, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; COLON; COLORECTAL NEOPLASMS; DIET; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LIFE STYLE; MICROSATELLITE INSTABILITY; PROTECTIVE FACTORS; RISK ASSESSMENT; RISK FACTORS; SMOKING;

EID: 84920155009     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i48.18151     Document Type: Article

References (153)

1. Jemal A, Center MM, Ward E, Thun MJ. Cancer occurrence. Methods Mol Biol 2009; 471: 3-29 [PMID: 19109772 DOI: 10.10 07/978-1-59745-416-2-1]
2. Bingham SA, Day NE, Luben R, Ferrari P, Slimani N, Norat T, Clavel-Chapelon F, Kesse E, Nieters A, Boeing H, Tjonneland A, Overvad K, Martinez C, Dorronsoro M, Gonzalez CA, Key TJ, Trichopoulou A, Naska A, Vineis P, Tumino R, Krogh V, Bueno-de-Mesquita HB, Peeters PH, Berglund G, Hallmans G, Lund E, Skeie G, Kaaks R, Riboli E. Dietary fibre in food and protection against colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC): an observational study. Lancet 2003; 361: 1496-1501 [PMID: 12737858]
3. Terzić J, Grivennikov S, Karin E, Karin M. Inflammation and colon cancer. Gastroenterology 2010; 138: 2101-2114.e5 [PMID: 20420949 DOI: 10.1053/j.gastro.2010.01.058]
4. Candela M, Turroni S, Biagi E, Carbonero F, Rampelli S, Fiorentini C, Brigidi P. Inflammation and colorectal cancer, when microbiota-host mutualism breaks. World J Gastroenterol 2014; 20: 908-922 [PMID: 24574765 DOI: 10.3748/wjg.v20.i4.908]
5. zur Hausen H. Red meat consumption and cancer: reasons to suspect involvement of bovine infectious factors in colorectal cancer. Int J Cancer 2012; 130: 2475-2483 [PMID: 22212999 DOI: 10.1002/ijc.27413]
6. van de Velde CJ, Boelens PG, Tanis PJ, Espin E, Mroczkowski P, Naredi P, Pahlman L, Ortiz H, Rutten HJ, Breugom AJ, Smith JJ, Wibe A, Wiggers T, Valentini V. Experts reviews of the multidisciplinary consensus conference colon and rectal cancer 2012: science, opinions and experiences from the experts of surgery. Eur J Surg Oncol 2014; 40: 454-468 [PMID: 24268926 DOI: 10.1016/j.ejso.2013.10.013]
7. Cummings JH, Pomare EW, Branch WJ, Naylor CP, Macfarlane GT. Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut 1987; 28: 1221-1227 [PMID: 3678950]
8. Koropatkin NM, Cameron EA, Martens EC. How glycan metabolism shapes the human gut microbiota. Nat Rev Microbiol 2012; 10: 323-335 [PMID: 22491358 DOI: 10.1038/ nrmicro2746]
9. Rowland IR. The role of the gastrointestinal microbiota in colorectal cancer. Curr Pharm Des 2009; 15: 1524-1527 [PMID: 19442169]
10. Zhao R, Michor F. Patterns of proliferative activity in the colonic crypt determine crypt stability and rates of somatic evolution. PLoS Comput Biol 2013; 9: e1003082 [PMID: 23785264 DOI: 10.1371/journal.pcbi.1003082]
11. Potten CS, Kellett M, Roberts SA, Rew DA, Wilson GD. Measurement of in vivo proliferation in human colorectal mucosa using bromodeoxyuridine. Gut 1992; 33: 71-78 [PMID: 1740282]
12. Wilson TJ, Ponder BA, Wright NA. Use of a mouse chimaeric model to study cell migration patterns in the small intestinal epithelium. Cell Tissue Kinet 1985; 18: 333-344 [PMID: 3986874]
13. David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, Ling AV, Devlin AS, Varma Y, Fischbach MA, Biddinger SB, Dutton RJ, Turnbaugh PJ. Diet rapidly and reproducibly alters the human gut microbiome. Nature 2014; 505: 559-563 [PMID: 24336217 DOI: 10.1038/nature12820]
14. Bustos Fernandez LM, Lasa JS, Man F. Intestinal microbiota: its role in digestive diseases. J Clin Gastroenterol 2014; 48: 657-666 [PMID: 24921207 DOI: 10.1097/MCG.0000000000000153]
15. Madupu R, Szpakowski S, Nelson KE. Microbiome in human health and disease. Sci Prog 2013; 96: 153-170 [PMID: 23901633]
16. Robles Alonso V, Guarner F. Linking the gut microbiota to human health. Br J Nutr 2013; 109 Suppl 2: S21-S26 [PMID: 23360877 DOI: 10.1017/S0007114512005235]
17. Tremaroli V, Bäckhed F. Functional interactions between the gut microbiota and host metabolism. Nature 2012; 489: 242-249 [PMID: 22972297 DOI: 10.1038/nature11552]
18. Willyard C. Microbiome: Gut reaction. Nature 2011; 479: S5-7
19. Maynard CL, Elson CO, Hatton RD, Weaver CT. Reciprocal interactions of the intestinal microbiota and immune system. Nature 2012; 489: 231-241 [PMID: 22972296 DOI: 10.1038/ nature11551]
20. Ahn J, Sinha R, Pei Z, Dominianni C, Wu J, Shi J, Goedert JJ, Hayes RB, Yang L. Human gut microbiome and risk for colorectal cancer. J Natl Cancer Inst 2013; 105: 1907-1911 [PMID: 24316595 DOI: 10.1093/jnci/djt300]
21. Zackular JP, Baxter NT, Iverson KD, Sadler WD, Petrosino JF, Chen GY, Schloss PD. The gut microbiome modulates colon tumorigenesis. MBio 2013; 4: e00692-e00613 [PMID: 24194538 DOI: 10.1128/mBio.00692-13]
22. Birkett A, Muir J, Phillips J, Jones G, O'Dea K. Resistant starch lowers fecal concentrations of ammonia and phenols in humans. Am J Clin Nutr 1996; 63: 766-772 [PMID: 8615362]
23. Fung KY, Ooi CC, Zucker MH, Lockett T, Williams DB, Cosgrove LJ, Topping DL. Colorectal carcinogenesis: a cellular response to sustained risk environment. Int J Mol Sci 2013; 14: 13525-13541 [PMID: 23807509 DOI: 10.3390/ ijms140713525]
24. Leonel AJ, Alvarez-Leite JI. Butyrate: implications for intestinal function. Curr Opin Clin Nutr Metab Care 2012; 15: 474-479 [PMID: 22797568 DOI: 10.1097/MCO.0b013e32835665fa]
25. World Cancer Research Fund, American Institute for Cancer Research. Continous Update Project Report. Food, Nutrition, Physical Activity, and the Prevention of Colorectal Cancer 2011. Available from: URL: http://www.aicr.org/reduce-your-cancer-risk/recommendations-for-cancer-prevention/
26. Al-Lahham SH, Peppelenbosch MP, Roelofsen H, Vonk RJ, Venema K. Biological effects of propionic acid in humans; metabolism, potential applications and underlying mechanisms. Biochim Biophys Acta 2010; 1801: 1175-1183 [PMID: 20691280 DOI: 10.1016/j.bbalip.2010.07.007]
27. Lu H, Ouyang W, Huang C. Inflammation, a key event in cancer development. Mol Cancer Res 2006; 4: 221-233 [PMID: 16603636 DOI: 10.1158/1541-7786.MCR-05-0261]
28. Rao YK, Fang SH, Tzeng YM. Synthesis and biological evaluation of 3',4',5'-trimethoxychalcone analogues as inhibitors of nitric oxide production and tumor cell proliferation. Bioorg Med Chem 2009; 17: 7909-7914 [PMID: 19875299 DOI: 10.1016/j.bmc.2009.10.022]
29. Bastide NM, Pierre FH, Corpet DE. Heme iron from meat and risk of colorectal cancer: a meta-analysis and a review of the mechanisms involved. Cancer Prev Res (Phila) 2011; 4: 177-184 [PMID: 21209396 DOI: 10.1158/1940-6207.CAPR-10-0113]
30. Lewin MH, Bailey N, Bandaletova T, Bowman R, Cross AJ, Pollock J, Shuker DE, Bingham SA. Red meat enhances the colonic formation of the DNA adduct O6-carboxymethyl guanine: implications for colorectal cancer risk. Cancer Res 2006; 66: 1859-1865 [PMID: 16452248 DOI: 10.1158/0008-5472.CAN-05-2237]
31. Reddy BS, Hanson D, Mangat S, Mathews L, Sbaschnig M, Sharma C, Simi B. Effect of high-fat, high-beef diet and of mode of cooking of beef in the diet on fecal bacterial enzymes and fecal bile acids and neutral sterols. J Nutr 1980; 110: 1880-1887 [PMID: 7411244]
32. Crowther JS, Drasar BS, Hill MJ, Maclennan R, Magnin D, Peach S, Teoh-chan CH. Faecal steroids and bacteria and large bowel cancer in Hong Kong by socio-economic groups. Br J Cancer 1976; 34: 191-198 [PMID: 962996]
33. Hill MJ, Drasar BS, Hawksworth G, Aries V, Crowther JS, Williams RE. Bacteria and aetiology of cancer of large bowel. Lancet 1971; 1: 95-100 [PMID: 4099643]
34. Hill MJ, Taylor AJ, Thompson MH, Wait R. Fecal steroids and urinary volatile phenols in four Scandinavian populations. Nutr Cancer 1982; 4: 67-73 [PMID: 7155919 DOI: 10.1080/01635588209513740]
35. Reddy BS, Wynder EL. Large-bowel carcinogenesis: fecal constituents of populations with diverse incidence rates of colon cancer. J Natl Cancer Inst 1973; 50: 1437-1442 [PMID: 4717561]
36. Bernstein H, Bernstein C, Payne CM, Dvorak K. Bile acids as endogenous etiologic agents in gastrointestinal cancer. World J Gastroenterol 2009; 15: 3329-3340 [PMID: 19610133]
37. Payne CM, Bernstein C, Dvorak K, Bernstein H. Hydrophobic bile acids, genomic instability, Darwinian selection, and colon carcinogenesis. Clin Exp Gastroenterol 2008; 1: 19-47 [PMID: 21677822]
38. Payne CM, Crowley-Skillicorn C, Bernstein C, Holubec H, Moyer MP, Bernstein H. Hydrophobic bile acid-induced micronuclei formation, mitotic perturbations, and decreases in spindle checkpoint proteins: relevance to genomic instability in colon carcinogenesis. Nutr Cancer 2010; 62: 825-840 [PMID: 20661832 DOI: 10.1080/01635581003695756]
39. Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med 2003; 348: 919-932 [PMID: 12621137 DOI: 10.1056/ NEJMra012242]
40. Weitz J, Koch M, Debus J, Höhler T, Galle PR, Büchler MW. Colorectal cancer. Lancet 2005; 365: 153-165 [PMID: 15639298 DOI: 10.1016/S0140-6736(05)17706-X]
41. Alexander DD, Miller AJ, Cushing CA, Lowe KA. Processed meat and colorectal cancer: a quantitative review of prospective epidemiologic studies. Eur J Cancer Prev 2010; 19: 328-341 [PMID: 20495462 DOI: 10.1097/CEJ.0b013e32833b48fa]
42. Alexander DD, Weed DL, Cushing CA, Lowe KA. Metaanalysis of prospective studies of red meat consumption and colorectal cancer. Eur J Cancer Prev 2011; 20: 293-307 [PMID: 21540747 DOI: 10.1097/CEJ.0b013e328345f985]
43. Cross AJ, Ferrucci LM, Risch A, Graubard BI, Ward MH, Park Y, Hollenbeck AR, Schatzkin A, Sinha R. A large prospective study of meat consumption and colorectal cancer risk: an investigation of potential mechanisms underlying this association. Cancer Res 2010; 70: 2406-2414 [PMID: 20215514 DOI: 10.1158/0008-5472.CAN-09-3929]
44. World Cancer Research Fund, American Institute for Cancer Research. Food, Nutrition, Physical Activity and the Prevention of Cancer: A Global Perspective 2007. Available from: URL: http://www.dietandcancerreport.org/cancer-resource-center/downloads/Second-Expert-Re port-full.pdf
45. Norat T, Chan D, Lau R, Aune D, Vieira R. The Association Between Food, Nutrition and Physical Activity and the Risk of Colorectal Cancer. WCRF/AICR Systematic Literature Review Continous Update Project Report. London: World Cancer Research Fund/American Insitute for Cancer Research, 2010
46. Ben Q, Sun Y, Chai R, Qian A, Xu B, Yuan Y. Dietary fiber intake reduces risk for colorectal adenoma: a meta-analysis. Gastroenterology 2014; 146: 689-699.e6 [PMID: 24216326 DOI: 10.1053/j.gastro.2013.11.003]
47. Aune D, Chan DS, Lau R, Vieira R, Greenwood DC, Kampman E, Norat T. Dietary fibre, whole grains, and risk of colorectal cancer: systematic review and dose-response meta-analysis of prospective studies. BMJ 2011; 343: d6617 [PMID: 22074852 DOI: 10.1136/bmj.d6617]
48. US Department of Agriculture, National Agricultural Library and National Academy of Sciences, Institute of Medicine, Food and Nutrition Board. Dietary Reference Intakes for Energy, Carbohydrate, fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids (Macronutrients) 2005. Available from: URL: http://www.nal.usda.gov/fnic/DRI/DRI-Energy/energy-full-report.pdf
49. Anderson JW, Baird P, Davis RH, Ferreri S, Knudtson M, Koraym A, Waters V, Williams CL. Health benefits of dietary fiber. Nutr Rev 2009; 67: 188-205 [PMID: 19335713 DOI: 10.1111/j.1753-4887.2009.00189.x]
50. Eswaran S, Muir J, Chey WD. Fiber and functional gastrointestinal disorders. Am J Gastroenterol 2013; 108: 718-727 [PMID: 23545709 DOI: 10.1038/ajg.2013.63]
51. Gonlachanvit S, Coleski R, Owyang C, Hasler W. Inhibitory actions of a high fibre diet on intestinal gas transit in healthy volunteers. Gut 2004; 53: 1577-1582 [PMID: 15479674 DOI: 10.1136/gut.2004.041632]
52. Kamada N, Seo SU, Chen GY, Núñez G. Role of the gut microbiota in immunity and inflammatory disease. Nat Rev Immunol 2013; 13: 321-335 [PMID: 23618829 DOI: 10.1038/ nri3430]
53. Botteri E, Iodice S, Bagnardi V, Raimondi S, Lowenfels AB, Maisonneuve P. Smoking and colorectal cancer: a metaanalysis. JAMA 2008; 300: 2765-2778 [PMID: 19088354 DOI: 10.1001/jama.2008.839]
54. Cancer Care Ontario. Cancer Fact. Smoking responsible for a large proportion of new cancer cases in Ontario 2014. Available from: URL: http://cancercare.on.ca/cancerfacts/
55. Jensen K, Afroze S, Munshi MK, Guerrier M, Glaser SS. Mechanisms for nicotine in the development and progression of gastrointestinal cancers. Transl Gastrointest Cancer 2012; 1: 81-87 [PMID: 22701817 DOI: 10.3978/j.issn.2224-4778.2011.12.01]
56. Schütze M, Boeing H, Pischon T, Rehm J, Kehoe T, Gmel G, Olsen A, Tjønneland AM, Dahm CC, Overvad K, Clavel-Chapelon F, Boutron-Ruault MC, Trichopoulou A, Benetou V, Zylis D, Kaaks R, Rohrmann S, Palli D, Berrino F, Tumino R, Vineis P, Rodríguez L, Agudo A, Sánchez MJ, Dorronsoro M, Chirlaque MD, Barricarte A, Peeters PH, van Gils CH, Khaw KT, Wareham N, Allen NE, Key TJ, Boffetta P, Slimani N, Jenab M, Romaguera D, Wark PA, Riboli E, Bergmann MM. Alcohol attributable burden of incidence of cancer in eight European countries based on results from prospective cohort study. BMJ 2011; 342: d1584 [PMID: 21474525 DOI: 10.1136/bmj.d1584]
57. Moskal A, Norat T, Ferrari P, Riboli E. Alcohol intake and colorectal cancer risk: a dose-response meta-analysis of published cohort studies. Int J Cancer 2007; 120: 664-671 [PMID: 17096321 DOI: 10.1002/ijc.22299]
58. Cho E, Smith-Warner SA, Ritz J, van den Brandt PA, Colditz GA, Folsom AR, Freudenheim JL, Giovannucci E, Goldbohm RA, Graham S, Holmberg L, Kim DH, Malila N, Miller AB, Pietinen P, Rohan TE, Sellers TA, Speizer FE, Willett WC, Wolk A, Hunter DJ. Alcohol intake and colorectal cancer: a pooled analysis of 8 cohort studies. Ann Intern Med 2004; 140: 603-613 [PMID: 15096331]
59. Boffetta P, Hashibe M. Alcohol and cancer. Lancet Oncol 2006; 7: 149-156 [PMID: 16455479 DOI: 10.1016/S1470-2045(06)70577-0]
60. Wiseman M. The second World Cancer Research Fund/ American Institute for Cancer Research expert report. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Proc Nutr Soc 2008; 67: 253-256 [PMID: 18452640 DOI: 10.1017/S002966510800712X]
61. Sun Z, Liu L, Wang PP, Roebothan B, Zhao J, Dicks E, Cotterchio M, Buehler S, Campbell PT, McLaughlin JR, Parfrey PS. Association of total energy intake and macronutrient consumption with colorectal cancer risk: results from a large population-based case-control study in Newfoundland and Labrador and Ontario, Canada. Nutr J 2012; 11: 18 [PMID: 22449145 DOI: 10.1186/1475-2891-11-18]
62. Medzhitov R. Origin and physiological roles of inflammation. Nature 2008; 454: 428-435 [PMID: 18650913 DOI: 10.1038/ nature07201]
63. Ostan R, Bucci L, Capri M, Salvioli S, Scurti M, Pini E, Monti D, Franceschi C. Immunosenescence and immunogenetics of human longevity. Neuroimmunomodulation 2008; 15: 224-240 [PMID: 19047800 DOI: 10.1159/000156466]
64. Larbi A, Franceschi C, Mazzatti D, Solana R, Wikby A, Pawelec G. Aging of the immune system as a prognostic factor for human longevity. Physiology (Bethesda) 2008; 23: 64-74 [PMID: 18400689 DOI: 10.1152/physiol.00040.2007]
65. Guigoz Y, Doré J, Schiffrin EJ. The inflammatory status of old age can be nurtured from the intestinal environment. Curr Opin Clin Nutr Metab Care 2008; 11: 13-20 [PMID: 18090652 DOI: 10.1097/MCO.0b013e3282f2bfdf]
66. Sansonetti PJ. To be or not to be a pathogen: that is the mucosally relevant question. Mucosal Immunol 2011; 4: 8-14 [PMID: 21150896 DOI: 10.1038/mi.2010.77]
67. Schwabe RF, Wang TC. Cancer. Bacteria deliver a genotoxic hit. Science 2012; 338: 52-53 [PMID: 23042875 DOI: 10.1126/ science.1229905]
68. Kato I, Majumdar AP, Land SJ, Barnholtz-Sloan JS, Severson RK. Dietary fatty acids, luminal modifiers, and risk of colorectal cancer. Int J Cancer 2010; 127: 942-951 [PMID: 19998336 DOI: 10.1002/ijc.25103]
69. Nkondjock A, Shatenstein B, Maisonneuve P, Ghadirian P. Specific fatty acids and human colorectal cancer: an overview. Cancer Detect Prev 2003; 27: 55-66 [PMID: 12600418]
70. Jones MK, Wang H, Peskar BM, Levin E, Itani RM, Sarfeh IJ, Tarnawski AS. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 1999; 5: 1418-1423 [PMID: 10581086 DOI: 10.1038/70995]
71. Berstad P, Thiis-Evensen E, Vatn MH, Almendingen K. Fatty acids in habitual diet, plasma phospholipids, and tumour and normal colonic biopsies in young colorectal cancer patients. J Oncol 2012; 2012: 254801 [PMID: 23319946 DOI: 10.1155/2012/254801]
72. Cathcart MC, Lysaght J, Pidgeon GP. Eicosanoid signalling pathways in the development and progression of colorectal cancer: novel approaches for prevention/intervention. Cancer Metastasis Rev 2011; 30: 363-385 [PMID: 22134655 DOI: 10.1007/s10555-011-9324-x]
73. Nolfo F, Rametta S, Marventano S, Grosso G, Mistretta A, Drago F, Gangi S, Basile F, Biondi A. Pharmacological and dietary prevention for colorectal cancer. BMC Surg 2013; 13 Suppl 2: S16 [PMID: 24267792 DOI: 10.1186/1471-2482-13-S2-S16]
74. Nakanishi M, Menoret A, Tanaka T, Miyamoto S, Montrose DC, Vella AT, Rosenberg DW. Selective PGE(2) suppression inhibits colon carcinogenesis and modifies local mucosal immunity. Cancer Prev Res (Phila) 2011; 4: 1198-1208 [PMID: 21576350 DOI: 10.1158/1940-6207.CAPR-11-0188]
75. Bultman SJ. Emerging roles of the microbiome in cancer. Carcinogenesis 2014; 35: 249-255 [PMID: 24302613 DOI: 10.1093/carcin/bgt392]
76. Tjalsma H, Boleij A, Marchesi JR, Dutilh BE. A bacterial driver-passenger model for colorectal cancer: beyond the usual suspects. Nat Rev Microbiol 2012; 10: 575-582 [PMID: 22728587 DOI: 10.1038/nrmicro2819]
77. Khare S, Verma M. Epigenetics of colon cancer. Methods Mol Biol 2012; 863: 177-185 [PMID: 22359293 DOI: 10.1007/978-1- 61779-612-8-10]
78. Pancione M, Remo A, Colantuoni V. Genetic and epigenetic events generate multiple pathways in colorectal cancer progression. Patholog Res Int 2012; 2012: 509348 [PMID: 22888469 DOI: 10.1155/2012/509348]
79. Spilianakis CG, Lalioti MD, Town T, Lee GR, Flavell RA. Interchromosomal associations between alternatively expressed loci. Nature 2005; 435: 637-645 [PMID: 15880101 DOI: 10.1038/nature03574]
80. Barnes DE, Lindahl T. Repair and genetic consequences of endogenous DNA base damage in mammalian cells. Annu Rev Genet 2004; 38: 445-476 [PMID: 15568983 DOI: 10.1146/ annurev.genet.38.072902.092448]
81. Lang T, Maitra M, Starcevic D, Li SX, Sweasy JB. A DNA polymerase beta mutant from colon cancer cells induces mutations. Proc Natl Acad Sci USA 2004; 101: 6074-6079 [PMID: 15075389 DOI: 10.1073/pnas.0308571101]
82. Wang S, El-Deiry WS. Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy. Proc Natl Acad Sci USA 2003; 100: 15095-15100 [PMID: 14645705 DOI: 10.1073/pnas.2435285100]
83. Richardson RB. p53 mutations associated with aging-related rise in cancer incidence rates. Cell Cycle 2013; 12: 2468-2478 [PMID: 23839036 DOI: 10.4161/cc.25494]
84. Shin YJ, Chen KY, Sayed AH, Hencey B, Shen X. Posttranslational regulation enables robust p53 regulation. BMC Syst Biol 2013; 7: 83 [PMID: 23992617 DOI: 10.1186/1752-0509-7-83]
85. Blanpain C. Tracing the cellular origin of cancer. Nat Cell Biol 2013; 15: 126-134 [PMID: 23334500 DOI: 10.1038/ncb2657]
86. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-767 [PMID: 2188735]
87. Armaghany T, Wilson JD, Chu Q, Mills G. Genetic alterations in colorectal cancer. Gastrointest Cancer Res 2012; 5: 19-27 [PMID: 22574233]
88. Dobre M, Comãnescu M, Arsene D, Iosif C, Bussolati G. K-ras gene mutation status in colorectal cancer: comparative analysis of pyrosequencing and PCR-RFLP. Rom J Morphol Embryol 2013; 54: 567-574 [PMID: 24068405]
89. Bettington M, Walker N, Clouston A, Brown I, Leggett B, Whitehall V. The serrated pathway to colorectal carcinoma: current concepts and challenges. Histopathology 2013; 62: 367-386 [PMID: 23339363 DOI: 10.1111/his.12055]
90. Leggett B, Whitehall V. Role of the serrated pathway in colorectal cancer pathogenesis. Gastroenterology 2010; 138: 2088-2100 [PMID: 20420948 DOI: 10.1053/j.gastro.2009.12.066]
91. Moon BS, Jeong WJ, Park J, Kim TI, Min do S, Choi KY. Role of oncogenic K-Ras in cancer stem cell activation by aberrant Wnt/β-catenin signaling. J Natl Cancer Inst 2014; 106: djt373 [PMID: 24491301 DOI: 10.1093/jnci/djt373]
92. Alrawi SJ, Schiff M, Carroll RE, Dayton M, Gibbs JF, Kulavlat M, Tan D, Berman K, Stoler DL, Anderson GR. Aberrant crypt foci. Anticancer Res 2006; 26: 107-119 [PMID: 16475686]
93. Feng Y, Bommer GT, Zhao J, Green M, Sands E, Zhai Y, Brown K, Burberry A, Cho KR, Fearon ER. Mutant KRAS promotes hyperplasia and alters differentiation in the colon epithelium but does not expand the presumptive stem cell pool. Gastroenterology 2011; 141: 1003-1013.e1-10 [PMID: 21699772 DOI: 10.1053/j.gastro.2011.05.007]
94. Otori K, Oda Y, Sugiyama K, Hasebe T, Mukai K, Fujii T, Tajiri H, Yoshida S, Fukushima S, Esumi H. High frequency of K-ras mutations in human colorectal hyperplastic polyps. Gut 1997; 40: 660-663 [PMID: 9203947]
95. Grady WM, Carethers JM. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology 2008; 135: 1079-1099 [PMID: 18773902 DOI: 10.1053/ j.gastro.2008.07.076]
96. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004; 10: 789-799 [PMID: 15286780 DOI: 10.1038/nm1087]
97. Markman B, Javier Ramos F, Capdevila J, Tabernero J. EGFR and KRAS in colorectal cancer. Adv Clin Chem 2010; 51: 71-119 [PMID: 20857619]
98. Bond CE, Nancarrow DJ, Wockner LF, Wallace L, Montgomery GW, Leggett BA, Whitehall VL. Microsatellite stable colorectal cancers stratified by the BRAF V600E mutation show distinct patterns of chromosomal instability. PLoS One 2014; 9: e91739 [PMID: 24651849 DOI: 10.1371/journal.pone.0091739]
99. Sideris M, Papagrigoriadis S. Molecular biomarkers and classification models in the evaluation of the prognosis of colorectal cancer. Anticancer Res 2014; 34: 2061-2068 [PMID: 24778007]
100. van Heemst D, den Reijer PM, Westendorp RG. Ageing or cancer: a review on the role of caretakers and gatekeepers. Eur J Cancer 2007; 43: 2144-2152 [PMID: 17764928 DOI: 10.1016/j.ejca.2007.07.011]
101. Alberici P, Fodde R. The role of the APC tumor suppressor in chromosomal instability. Genome Dyn 2006; 1: 149-170 [PMID: 18724059 DOI: 10.1159/000092506]
102. Fearnhead NS, Britton MP, Bodmer WF. The ABC of APC. Hum Mol Genet 2001; 10: 721-733 [PMID: 11257105]
103. Aoki K, Taketo MM. Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene. J Cell Sci 2007; 120: 3327-3335 [PMID: 17881494 DOI: 10.1242/jcs.03485]
104. Barker N, Ridgway RA, van Es JH, van de Wetering M, Begthel H, van den Born M, Danenberg E, Clarke AR, Sansom OJ, Clevers H. Crypt stem cells as the cells-oforigin of intestinal cancer. Nature 2009; 457: 608-611 [PMID: 19092804 DOI: 10.1038/nature07602]
105. Jass JR. Pathogenesis of colorectal cancer. Surg Clin North Am 2002; 82: 891-904 [PMID: 12507199]
106. Worthley DL, Whitehall VL, Spring KJ, Leggett BA. Colorectal carcinogenesis: road maps to cancer. World J Gastroenterol 2007; 13: 3784-3791 [PMID: 17657831]
107. Tian X, Liu Z, Niu B, Zhang J, Tan TK, Lee SR, Zhao Y, Harris DC, Zheng G. E-cadherin/β-catenin complex and the epithelial barrier. J Biomed Biotechnol 2011; 2011: 567305 [PMID: 22007144 DOI: 10.1155/2011/567305]
108. Draviam VM, Shapiro I, Aldridge B, Sorger PK. Misorientation and reduced stretching of aligned sister kinetochores promote chromosome missegregation in EB1-or APC-depleted cells. EMBO J 2006; 25: 2814-2827 [PMID: 16763565 DOI: 10.1038/sj.emboj.7601168]
109. Kim YM, Park SY, Pyo H. Cyclooxygenase-2 (COX-2) negatively regulates expression of epidermal growth factor receptor and causes resistance to gefitinib in COX-2-overexpressing cancer cells. Mol Cancer Res 2009; 7: 1367-1377 [PMID: 19671676 DOI: 10.1158/1541-7786.MCR-09-0004]
110. Choi SH, Estarás C, Moresco JJ, Yates JR, Jones KA. α-Catenin interacts with APC to regulate β-catenin proteolysis and transcriptional repression of Wnt target genes. Genes Dev 2013; 27: 2473-2488 [PMID: 24240237 DOI: 10.1101/gad.229062.113]
111. Lüchtenborg M, Weijenberg MP, Roemen GM, de Bruïne AP, van den Brandt PA, Lentjes MH, Brink M, van Engeland M, Goldbohm RA, de Goeij AF. APC mutations in sporadic colorectal carcinomas from The Netherlands Cohort Study. Carcinogenesis 2004; 25: 1219-1226 [PMID: 14976131 DOI: 10.1093/carcin/bgh117]
112. Suzuki K, Matsubara H. Recent advances in p53 research and cancer treatment. J Biomed Biotechnol 2011; 2011: 978312 [PMID: 21765642 DOI: 10.1155/2011/978312]
113. Zilfou JT, Lowe SW. Tumor suppressive functions of p53. Cold Spring Harb Perspect Biol 2009; 1: a001883 [PMID: 20066118 DOI: 10.1101/cshperspect.a001883]
114. Amaral JD, Xavier JM, Steer CJ, Rodrigues CM. The role of p53 in apoptosis. Discov Med 2010; 9: 145-152 [PMID: 20193641]
115. Bahnassy AA, Zekri AR, Salem SE, Abou-Bakr AA, Sakr MA, Abdel-Samiaa AG, Al-Bradei M. Differential expression of p53 family proteins in colorectal adenomas and carcinomas: Prognostic and predictive values. Histol Histopathol 2014; 29: 207-216 [PMID: 23996743]
116. Suppiah A, Greenman J. Clinical utility of anti-p53 autoantibody: systematic review and focus on colorectal cancer. World J Gastroenterol 2013; 19: 4651-4670 [PMID: 23922463 DOI: 10.3748/wjg.v19.i29.4651]
117. Chen TH, Huang CC, Yeh KT, Chang SH, Chang SW, Sung WW, Cheng YW, Lee H. Human papilloma virus 16 E6 oncoprotein associated with p53 inactivation in colorectal cancer. World J Gastroenterol 2012; 18: 4051-4058 [PMID: 22912557 DOI: 10.3748/wjg.v18.i30.4051]
118. McBride KA, Ballinger ML, Killick E, Kirk J, Tattersall MH, Eeles RA, Thomas DM, Mitchell G. Li-Fraumeni syndrome: cancer risk assessment and clinical management. Nat Rev Clin Oncol 2014; 11: 260-271 [PMID: 24642672 DOI: 10.1038/ nrclinonc.2014.41]
119. Wimmer K, Kratz CP, Vasen HF, Caron O, Colas C, Entz-Werle N, Gerdes AM, Goldberg Y, Ilencikova D, Muleris M, Duval A, Lavoine N, Ruiz-Ponte C, Slavc I, Burkhardt B, Brugieres L. Diagnostic criteria for constitutional mismatch repair deficiency syndrome: suggestions of the European consortium 'care for CMMRD' (C4CMMRD). J Med Genet 2014; 51: 355-365 [PMID: 24737826 DOI: 10.1136/ jmedgenet-2014-102284]
120. Carethers JM. Differentiating Lynch-like from Lynch syndrome. Gastroenterology 2014; 146: 602-604 [PMID: 24468183 DOI: 10.1053/j.gastro.2014.01.041]
121. Poulogiannis G, Frayling IM, Arends MJ. DNA mismatch repair deficiency in sporadic colorectal cancer and Lynch syndrome. Histopathology 2010; 56: 167-179 [PMID: 20102395 DOI: 10.1111/j.1365-2559.2009.03392.x]
122. Jeffreys AJ, Wilson V, Thein SL. Hypervariable 'minisatellite' regions in human DNA. Nature 1985; 314: 67-73 [PMID: 3856104]
123. Li YC, Korol AB, Fahima T, Beiles A, Nevo E. Microsatellites: genomic distribution, putative functions and mutational mechanisms: a review. Mol Ecol 2002; 11: 2453-2465 [PMID: 12453231]
124. Viguera E, Canceill D, Ehrlich SD. Replication slippage involves DNA polymerase pausing and dissociation. EMBO J 2001; 20: 2587-2595 [PMID: 11350948 DOI: 10.1093/ emboj/20.10.2587]
125. Hitchins MP, Lynch HT. Dawning of the epigenetic era in hereditary cancer. Clin Genet 2014; 85: 413-416 [PMID: 24588205 DOI: 10.1111/cge.12369]
126. Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Rüschoff J, Fishel R, Lindor NM, Burgart LJ, Hamelin R, Hamilton SR, Hiatt RA, Jass J, Lindblom A, Lynch HT, Peltomaki P, Ramsey SD, Rodriguez-Bigas MA, Vasen HF, Hawk ET, Barrett JC, Freedman AN, Srivastava S. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004; 96: 261-268 [PMID: 14970275]
127. Nielsen M, Morreau H, Vasen HF, Hes FJ. MUTYHassociated polyposis (MAP). Crit Rev Oncol Hematol 2011; 79: 1-16 [PMID: 20663686 DOI: 10.1016/j.critrevonc.2010.05.011]
128. Jones N, Vogt S, Nielsen M, Christian D, Wark PA, Eccles D, Edwards E, Evans DG, Maher ER, Vasen HF, Hes FJ, Aretz S, Sampson JR. Increased colorectal cancer incidence in obligate carriers of heterozygous mutations in MUTYH. Gastroenterology 2009; 137: 489-94, 494.e1; quiz 725-6 [PMID: 19394335 DOI: 10.1053/j.gastro.2009.04.047]
129. Win AK, Hopper JL, Jenkins MA. Association between monoallelic MUTYH mutation and colorectal cancer risk: a meta-regression analysis. Fam Cancer 2011; 10: 1-9 [PMID: 21061173 DOI: 10.1007/s10689-010-9399-5]
130. Balaguer F, Castellví-Bel S, Castells A, Andreu M, Muñoz J, Gisbert JP, Llor X, Jover R, de Cid R, Gonzalo V, Bessa X, Xicola RM, Pons E, Alenda C, Payá A, Piqué JM. Identification of MYH mutation carriers in colorectal cancer: a multicenter, case-control, population-based study. Clin Gastroenterol Hepatol 2007; 5: 379-387 [PMID: 17368238 DOI: 10.1016/j.cgh.2006.12.025]
131. Aretz S, Uhlhaas S, Goergens H, Siberg K, Vogel M, Pagenstecher C, Mangold E, Caspari R, Propping P, Friedl W. MUTYH-associated polyposis: 70 of 71 patients with biallelic mutations present with an attenuated or atypical phenotype. Int J Cancer 2006; 119: 807-814 [PMID: 16557584 DOI: 10.1002/ijc.21905]
132. Morak M, Laner A, Bacher U, Keiling C, Holinski-Feder E. MUTYH-associated polyposis - variability of the clinical phenotype in patients with biallelic and monoallelic MUTYH mutations and report on novel mutations. Clin Genet 2010; 78: 353-363 [PMID: 20618354 DOI: 10.1111/ j.1399-0004.2010.01478.x]
133. Heinemann V, Stintzing S, Kirchner T, Boeck S, Jung A. Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR. Cancer Treat Rev 2009; 35: 262-271 [PMID: 19117687 DOI: 10.1016/j.ctrv.2008.11.005]
134. Deller MC, Yvonne Jones E. Cell surface receptors. Curr Opin Struct Biol 2000; 10: 213-219 [PMID: 10753817]
135. Cooper GM. The Cell: A Molecular Approach. 2nd ed. Sunderland (MA): Sinauer Associates, 2000
136. Burgess AW, Henis YI, Hynes NE, Jovin T, Levitzki A, Pinkas-Kramarski R, Yarden Y. EGF receptor family: twisting targets for improved cancer therapies. Growth Factors 2014; 32: 74-81 [PMID: 24641597 DOI: 10.3109/08977194.2014.896355]
137. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001; 7: 2958-2970 [PMID: 11595683]
138. Di Fiore F, Sesboüé R, Michel P, Sabourin JC, Frebourg T. Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer. Br J Cancer 2010; 103: 1765-1772 [PMID: 21139621 DOI: 10.1038/sj.bjc.6606008]
139. Oda K, Matsuoka Y, Funahashi A, Kitano H. A comprehensive pathway map of epidermal growth factor receptor signaling. Mol Syst Biol 2005; 1: 2005.0010 [PMID: 16729045 DOI: 10.1038/msb4100014]
140. Walker F, Abramowitz L, Benabderrahmane D, Duval X, Descatoire V, Hénin D, Lehy T, Aparicio T. Growth factor receptor expression in anal squamous lesions: modifications associated with oncogenic human papillomavirus and human immunodeficiency virus. Hum Pathol 2009; 40: 1517-1527 [PMID: 19716155 DOI: 10.1016/j.humpath.2009.05.010]
141. Shi C, Washington K. Molecular testing in colorectal cancer: diagnosis of Lynch syndrome and personalized cancer medicine. Am J Clin Pathol 2012; 137: 847-859 [PMID: 22586043 DOI: 10.1309/AJCPI83DINULUJNI]
142. Haraldsdottir S, Bekaii-Saab T. Integrating anti-EGFR therapies in metastatic colorectal cancer. J Gastrointest Oncol 2013; 4: 285-298 [PMID: 23997940 DOI: 10.3978/j.issn.2078-6891.2013.028]
143. Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, Hamilton A, Pan D, Schrag D, Schwartz L, Klimstra DS, Fridman D, Kelsen DP, Saltz LB. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 23: 1803-1810 [PMID: 15677699 DOI: 10.1200/JCO.2005.08.037]
144. Krasinskas AM. EGFR Signaling in Colorectal Carcinoma. Patholog Res Int 2011; 2011: 932932 [PMID: 21403829 DOI: 10.4061/2011/932932]
145. Saltz LB, Meropol NJ, Loehrer PJ, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201-1208 [PMID: 14993230 DOI: 10.1200/JCO.2004.10.182]
146. Adams RH, Alitalo K. Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol 2007; 8: 464-478 [PMID: 17522591 DOI: 10.1038/nrm2183]
147. Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M, Neeman M, Bono F, Abramovitch R, Maxwell P, Koch CJ, Ratcliffe P, Moons L, Jain RK, Collen D, Keshert E. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998; 394: 485-490 [PMID: 9697772 DOI: 10.1038/28867]
148. Dewhirst MW. Relationships between cycling hypoxia, HIF-1, angiogenesis and oxidative stress. Radiat Res 2009; 172: 653-665 [PMID: 19929412 DOI: 10.1667/RR1926.1]
149. Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Cassidy J. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-2019 [PMID: 18421054 DOI: 10.1200/JCO.2007.14.9930]
150. Tebbutt NC, Wilson K, Gebski VJ, Cummins MM, Zannino D, van Hazel GA, Robinson B, Broad A, Ganju V, Ackland SP, Forgeson G, Cunningham D, Saunders MP, Stockler MR, Chua Y, Zalcberg JR, Simes RJ, Price TJ. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J Clin Oncol 2010; 28: 3191-3198 [PMID: 20516443 DOI: 10.1200/JCO.2009.27.7723]
151. Marques I, Araújo A, de Mello RA. Anti-angiogenic therapies for metastatic colorectal cancer: current and future perspectives. World J Gastroenterol 2013; 19: 7955-7971 [PMID: 24307789 DOI: 10.3748/wjg.v19.i44.7955]
152. Edwards PA. The impact of developmental biology on cancer research: an overview. Cancer Metastasis Rev 1999; 18: 175-180 [PMID: 10728982]
153. Lo RS, Wotton D, Massagué J. Epidermal growth factor signaling via Ras controls the Smad transcriptional corepressor TGIF. EMBO J 2001; 20: 128-136 [PMID: 11226163 DOI: 10.1093/emboj/20.1.128]